Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Development of endosome-related gene signature for the prediction of prognosis and therapeutic response in breast cancer.
Medicine (Baltimore)
January 2025
Department of Breast, Haining Maternity and Child Health Care Hospital, Haining, Zhejieng, China.
Endosomes play a pivotal role in cellular biology, orchestrating processes such as endocytosis, molecular trafficking, signal transduction, and recycling of cellular materials. This study aims to construct an endosome-related gene (ERG)-derived risk signature for breast cancer prognosis. Transcriptomic and clinical data were retrieved from The Cancer Genome Atlas and the University of California Santa Cruz databases to build and validate the model.
View Article and Find Full Text PDFUnveiling the molecular profile of a prostate carcinoma: implications for personalized medicine.
Biol Direct
December 2024
Urology Unit, Department of Surgery, Tor Vergata University of Rome, Rome, Italy.
Background: Prostate cancer is the most common diagnosed tumor and the fifth cancer related death among men in Europe. Although several genetic alterations such as ERG-TMPRSS2 fusion, MYC amplification, PTEN deletion and mutations in p53 and BRCA2 genes play a key role in the pathogenesis of prostate cancer, specific gene alteration signature that could distinguish indolent from aggressive prostate cancer or may aid in patient stratification for prognosis and/or clinical management of patients with prostate cancer is still missing. Therefore, here, by a multi-omics approach we describe a prostate cancer carrying the fusion of TMPRSS2 with ERG gene and deletion of 16q chromosome arm.
View Article and Find Full Text PDFAn evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Expert Rev Anticancer Ther
December 2024
Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Introduction: Prostate cancer (PCa) is the second most common cancer diagnosis among men worldwide, with poor prognosis in its advanced stage. Treatment strategies have evolved, including the use of androgen receptor pathway inhibitors (ARPIs) and poly (ADP-ribose) polymerase inhibitors (PARPis).
Areas Covered: This review evaluates the clinical efficacy, safety, and future potential of combining talazoparib, a potent PARPi, with enzalutamide, a strong androgen receptor (AR) antagonist.
ERG and PTEN Role on Active Surveillance for Low-Risk Prostate Cancer in the Multiparametric MRI Era.
Prostate
March 2025
Urology Department, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.
Background: Our study aimed to correlate ERG and PTEN expressions in prostate biopsy with multiparametric magnetic resonance imaging PI-RADS score, clinical reclassification, and prognosis of very low-risk prostate cancer (PCa) patients under active surveillance (AS).
Methods: We evaluated 101 very low-risk PCa patients under AS between 2013 and 2018. They were followed with DRE, PSA, MRI, and re-biopsies every 1-2 years.
Identification of SOX9-related prognostic DEGs and a prediction model for hepatitis C-induced early-stage fibrosis.
Gene
February 2025
Division of Liver Surgery, Department of General Surgery, West China Hospital, Si Chuan University, Chengdu, China. Electronic address:
Article Synopsis
- Hepatitis C virus infection leads to liver inflammation and fibrosis, with SOX9 overexpression linked to the activation of liver cells involved in fibrosis progression.
- Utilizing gene expression data from HCV patients, the study identified nine prognostic genes related to SOX9 that can predict disease outcomes, including both risk and protective factors.
- The newly developed prognostic model significantly outperforms existing methods for predicting patient outcomes, offering a novel approach to managing liver fibrosis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!